Arcus Must Prove Casdatifan's Frontline Story Still Holds

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

RCUS reports after market close, meaning Day 0 reflects anticipation before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price action shows moderate volatility around earnings, with an average absolute Day 0 move of 3.42% and Day +1 move of 2.16%. The stock has exhibited mixed directional bias, with the most recent earnings (August 2026) producing a 3.82% decline on Day 0 followed by a 2.27% gain on Day +1 after the company beat estimates.

The Day 0 range averages 6.74% while the Day +1 range averages 10.59%, indicating that the bulk of volatility often materializes in the session following the release as investors digest the results and management commentary. The largest single-day move in the dataset was a 9.17% decline in May 2025, demonstrating that RCUS can experience sharp drawdowns when results or guidance disappoint.

Part 2.2: Options Market Expected Move

The options market is pricing a 13.17% expected move for the November expiration, significantly higher than the historical average Day 0 move of 3.42% and even exceeding the average Day +1 range of 10.59%. This elevated implied volatility of 82.45% suggests options traders are anticipating above-average price action for this particular earnings event, likely reflecting heightened uncertainty around casdatifan trial updates and revenue guidance.

Part 3: What Analysts Are Saying

Current Analyst Consensus

Arcus Biosciences carries a Strong Buy consensus from Wall Street, with an average rating of 4.53 out of 5.0 across 17 analysts. The breakdown shows 13 Strong Buy ratings, 0 Moderate Buys, 4 Holds, and 0 Sell or Strong Sell ratings, reflecting overwhelming bullish sentiment despite the stock's recent underperformance.

The average price target of $39.85 implies 111% upside from the current price of $18.91, with estimates ranging from a low of $23.00 to a high of $50.00. This 117% spread between the highest and lowest targets reflects significant disagreement among analysts about the company's ultimate value, with the range widening as uncertainty around casdatifan's commercial potential and partnership economics persists.

Sentiment Evolution

Analyst sentiment has improved over the past month, with the number of Strong Buy ratings increasing from 11 to 13 while the Hold count remained steady at 4. The average recommendation strengthened from 4.47 to 4.53, indicating that recent clinical and partnership developments have reinforced the bullish case among sell-side analysts.

The $39.85 consensus target represents a substantial premium to the current trading level and suggests analysts believe the market is significantly undervaluing RCUS's pipeline potential, particularly the late-stage casdatifan program in renal cell carcinoma. However, the wide target range and the presence of four Hold ratings indicate that not all analysts share the conviction of the Strong Buy majority, with some likely waiting for clearer proof points on revenue trajectory and path to profitability.

Part 4: Technical Picture

Barchart Technical Opinion

The Barchart Technical Opinion has deteriorated sharply, moving from a 24% Sell signal one month ago to a 72% Sell signal one week ago and now standing at a 88% Sell signal currently. This rapid weakening reflects mounting technical pressure as the stock has broken below key support levels and failed to hold any meaningful rallies.

Timeframe Analysis

• Short-term (100% Sell): Maximum bearish signal indicates severe near-term downside momentum with no technical support
• Medium-term (100% Sell): Equally bearish intermediate-term reading confirms the downtrend is entrenched across multiple timeframes
• Long-term (50% Sell): Moderate sell signal suggests some longer-term structural support remains, though the trend is clearly negative

Trend Characteristics: The Strong signal strength combined with a Strengthening direction indicates the bearish trend is not only firmly established but actively intensifying heading into the earnings release.

Moving Average Analysis

RCUS is trading at $18.91, positioned above only the 5-day ($18.39) and 10-day ($18.49) moving averages while sitting below all longer-term averages. The stock trades below the 20-day ($20.89), 50-day ($24.50), 100-day ($26.48), and 200-day ($24.63) moving averages, with the current price representing a 23% discount to the 50-day average and a 29% discount to the 100-day average.

The technical setup is decidedly bearish heading into earnings, with the stock trading near its 52-week low of $17.43 and showing no signs of stabilization. The fact that RCUS is below all major moving averages except the shortest-term 5-day and 10-day readings indicates a complete breakdown of technical support, while the strengthening 88% Sell signal suggests momentum remains firmly to the downside. The 13.17% options-implied move creates a wide range from $16.42 to $21.40, and given the deteriorating technical picture, any earnings disappointment could push the stock toward or below the lower bound, potentially testing the 52-week low. Conversely, a strong beat with positive casdatifan updates would need to be substantial enough to overcome the entrenched bearish momentum and reclaim the 20-day moving average at $20.89 to signal a potential trend reversal.